Ruichen Rong

Dr. Ruichen Rong

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
RRRuichen Rong
Ruichen Rong
SWShidan Wang
Shidan Wang
XZXinyi Zhang
Xinyi Zhang
ZWZhuoyu Wen
Zhuoyu Wen
XCXian Cheng
Xian Cheng
Guanghua XiaoGuanghua Xiao
Guanghua Xiao

17 January 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SWShidan Wang
Shidan Wang
RRRuichen Rong
Ruichen Rong
DYDonghan M Yang
Donghan M Yang
Junya FujimotoJunya Fujimoto
Junya Fujimoto
JBJustin A. Bishop
Justin A. Bishop
YXYang Xie
Yang Xie
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective for many patients with lung cancer with EGFR mutations. However, not all patients are responsive to EGFR TKIs, including even those harboring EGFR-sensitizing mutations. In this study, we quantified the cells and cellular interaction features of the tumor microenvironment (TME) using routine H&E-stained biopsy sections. These TME features were used to develop a prediction model for survival benefit from EGFR TKI therapy in patients with lung adenocarcinoma and EGFR-sensitizing mutations in the Lung Cancer Mutation Consortium 1 (LCMC1) and validated in an independent LCMC2 cohort. In the validation data set, EGFR TKI treatment prolonged survival in the predicted-to-benefit group but not in the predicted-not-to-benefit group. Among patients treated with EGFR TKIs, the predicted-to-benefit group had prolonged survival outcomes compared with the predicted not-to-benefit group. The EGFR TKI survival benefit positively correlated with tumor-tumor interaction image features and negatively correlated with tumor-stroma interaction. Moreover, the tumor-stroma interaction was associated with higher activation of the hepatocyte growth factor/MET-mediated PI3K/AKT signaling pathway and epithelial-mesenchymal transition process, supporting the hypothesis of fibroblast-involved resistance to EGFR TKI treatment.


28 June 2022 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SYSen Yang
Sen Yang
SWShidan Wang
Shidan Wang
YWYiqing Wang
Yiqing Wang
RRRuichen Rong
Ruichen Rong
JKJiwoong Kim
Jiwoong Kim
XZXiaowei Zhan
Xiaowei Zhan

23 September 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
YGYanghong Guo
Yanghong Guo
BZBencong Zhu
Bencong Zhu
CTChen Tang
Chen Tang
RRRuichen Rong
Ruichen Rong
YMYing Ma
Ying Ma
Qiwei LiQiwei Li
Qiwei Li
The field of spatially resolved transcriptomics (SRT) has greatly advanced our understanding of cellular microenvironments by integrating spatial information with molecular data collected from multiple tissue sections or individuals. However, methods for multi-sample spatial clustering are lacking, and existing methods primarily rely on molecular information alone. This paper introduces BayeSMART, a Bayesian statistical method designed to identify spatial domains across multiple samples. BayeSMART leverages artificial intelligence (AI)-reconstructed single-cell level information from the paired histology images of multi-sample SRT datasets while simultaneously considering the spatial context of gene expression. The AI integration enables BayeSMART to effectively interpret the spatial domains. We conducted case studies using four datasets from various tissue types and SRT platforms, and compared BayeSMART with alternative multi-sample spatial clustering approaches and a number of state-of-the-art methods for single-sample SRT analysis, demonstrating that it surpasses existing methods in terms of clustering accuracy, interpretability, and computational efficiency. BayeSMART offers new insights into the spatial organization of cells in multi-sample SRT data.

28 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IMIsmael Villanueva Miranda
Ismael Villanueva Miranda
RRRuichen Rong
Ruichen Rong
PQPeiran Quan
Peiran Quan
ZWZhuoyu Wen
Zhuoyu Wen
XZXiaowei Zhan
Xiaowei Zhan
Guanghua XiaoGuanghua Xiao
Guanghua Xiao
Recent advances in foundation models have revolutionized model development in digital pathology, reducing dependence on extensive manual annotations required by traditional methods. The ability of foundation models to generalize well with few-shot learning addresses critical barriers in adapting models to diverse medical imaging tasks. This work presents the Granular Box Prompt Segment Anything Model (GB-SAM), an improved version of the Segment Anything Model (SAM) fine-tuned using granular box prompts with limited training data. The GB-SAM aims to reduce the dependency on expert pathologist annotators by enhancing the efficiency of the automated annotation process. Granular box prompts are small box regions derived from ground truth masks, conceived to replace the conventional approach of using a single large box covering the entire H&E-stained image patch. This method allows a localized and detailed analysis of gland morphology, enhancing the segmentation accuracy of individual glands and reducing the ambiguity that larger boxes might introduce in morphologically complex regions. We compared the performance of our GB-SAM model against U-Net trained on different sizes of the CRAG dataset. We evaluated the models across histopathological datasets, including CRAG, GlaS, and Camelyon16. GB-SAM consistently outperformed U-Net, with reduced training data, showing less segmentation performance degradation. Specifically, on the CRAG dataset, GB-SAM achieved a Dice coefficient of 0.885 compared to U-Net’s 0.857 when trained on 25% of the data. Additionally, GB-SAM demonstrated segmentation stability on the CRAG testing dataset and superior generalization across unseen datasets, including challenging lymph node segmentation in Camelyon16, which achieved a Dice coefficient of 0.740 versus U-Net’s 0.491. Furthermore, compared to SAM-Path and Med-SAM, GB-SAM showed competitive performance. GB-SAM achieved a Dice score of 0.900 on the CRAG dataset, while SAM-Path achieved 0.884. On the GlaS dataset, Med-SAM reported a Dice score of 0.956, whereas GB-SAM achieved 0.885 with significantly less training data. These results highlight GB-SAM’s advanced segmentation capabilities and reduced dependency on large datasets, indicating its potential for practical deployment in digital pathology, particularly in settings with limited annotated datasets.